首页> 美国政府科技报告 >Prospective Randomized Clinical Trial of Celecoxib for the Control of Symptomatic Plexiform Neurofibroma in Neurofibromatosis 1

【24h】

Prospective Randomized Clinical Trial of Celecoxib for the Control of Symptomatic Plexiform Neurofibroma in Neurofibromatosis 1

机译：塞来昔布用于控制神经纤维瘤病中症状性丛状神经纤维瘤的前瞻性随机临床试验1

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

The purpose of the project was to develop the infrastructure necessary to run a multi-center clinical trial of a novel medical therapy for patient with NF1. To this end, a consortium of seven institutions was developed, each with expertise in treating patients with NF1 or tumors of the nervous system. Important accomplishments include the establishment of a clinical protocol for running the trial; naming a Steering Committee, Data and Safety Monitoring Board, and Medical Monitor; and partnering with Pfizer, Inc, and PharmaContent, Inc. to run the trial. The protocol was submitted for approval at the Institutional Review Board at the sponsoring institution. This work culminated in the submission of a application for a Clinical Trial Award through the Department of Defense in June, 2005 (month 6 of the grant period).

著录项

作者
Gusella, J. F. ; Plotkin, S.;
展开▼
作者单位

展开▼
年度 2005
页码 1-6
总页数 6
原文格式 PDF
正文语种 eng
中图分类工业技术;
关键词
Medicine; Clinical trials; Monitoring; Random variables; Safety; Therapy; Nervous system; Internet;

机译：医学;临床试验;监测;随机变量;安全性;治疗;神经系统;互联网;

相似文献

外文文献
中文文献
专利

1. Phase 2 randomized, flexible crossover, double-blinded,placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas [J] . Brigitte C. Widemann, Eva Dombi, Andrea Gillespie, Neuro-Oncology . 2014,第5期

机译：法尼基转移酶抑制剂替非法尼在患有1型神经纤维瘤和进行性丛状神经纤维瘤的儿童和青少年中的2期随机，灵活，交叉，双盲，安慰剂对照试验
2. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study [J] . Weiss Brian, Widemann Brigitte C., Wolters Pamela, Neuro-Oncology . 2015,第4期

机译：西罗莫司治疗1型进行性神经纤维瘤病相关的丛状神经纤维瘤：神经纤维瘤病临床试验联盟II期研究
3. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas [J] . Weiss Brian D., Wolters Pamela L., Plotkin Scott R., Journal of Clinical Oncology . 2021,第7期

机译：NF106：一种神经纤维瘤病临床试验联盟II期II期梅克抑制剂MIRDAMetinib（PD-0325901）的青少年和成人与NF1相关的丛状神经纤维瘤
4. A Prospective Randomized Clinical Trial for Measuring Radiology Study Reporting Time on Artificial Intelligence-Based Detection of Intracranial Hemorrhage in Emergent Care Head CT [C] . Axel Wismüller, Larry Stockmaster Conference on Medical Imaging : Biomedical Applications in Molecular, Structural, and Functional Imaging . 2020

机译：一种预期随机临床试验，用于测量放射学研究报告时间对突出护理头CT中颅内出血的基于人工智能检测
5. Fissure Caries Inhibition with Solea CO 2 -9.3μm Short-Pulsed Laser - A Randomized, Single Blind, Prospective, Split Mouth Controlled, Clinical Trial [D] . Kubitz, Maxwell. 2019

机译：Solea CO 2-9.3μm短脉冲激光抑制龋齿的发生-随机，单盲，前瞻性，分口控制的临床试验
6. NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY [O] . Chie-Schin Shih, Jaishri Blakely, Wade Clapp, 2018

机译：NFM-01。 NF105：卡波替尼（XL184）用于患有多发性神经纤维症类型1的受试者的多形性神经纤维母细胞的II期前瞻性研究：神经纤维蛋白过少的临床试验药物
7. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas [O] . B. C. Widemann, E. Dombi, A. Gillespie, 2014

机译：第2阶段随机，灵活的交叉，双盲，沙呢基转移酶抑制剂的抑制剂刺激剂抑制剂，在儿童和年轻成人中，具有神经纤维瘤病的1型和渐进式的丛状神经纤维腈

Prospective Randomized Clinical Trial of Celecoxib for the Control of Symptomatic Plexiform Neurofibroma in Neurofibromatosis 1

摘要

著录项

相似文献

相关主题

期刊订阅